Tools   Select Another Resource Report Type

http://www.tissuenet.com/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on August 17,2021. Manufacturer of allograft tissue grafts in the United States in the ortho-biologics field of medicine. They develop new products for the patients they serve, including the UltraGraft non-irradiated & sterile line of allograft tissue implants., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: TissueNet (RRID:SCR_004489) Copy   

•   Source: SciCrunch Registry

http://primaryimmune.org/

National non-profit patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education and research. One of the greatest challenges faced by individuals diagnosed with primary immunodeficiency disease is finding the right information and resources when they need it. With knowledge and foresight from their personal experience, the Immune Deficiency Foundation (IDF) was founded by families of children with primary immunodeficiency diseases and their physicians to help meet those needs. It is with the spirit and energy of this keen perspective that IDF exists today, thriving as an organization dedicated to individuals living with primary immunodeficiencies. Since 1980, IDF has provided accurate and timely information for the nearly quarter-million Americans who have been diagnosed with a primary immunodeficiency disease. Governed by a Board of Trustees and supported by a Medical Advisory Committee comprised of some of the world''s leading clinical immunologists, as well as hundreds of grassroots volunteers and a compassionate, professional staff IDF has provided individuals and their families with vital knowledge and made tremendous strides in: * Helping the patient and medical community gain a broader understanding of primary immunodeficiency diseases through education and outreach efforts; * Promoting, participating, and funding research that has helped characterize primary immunodeficiency diseases and given patients and physicians substantially improved treatment options; * Addressing patient needs through public policy programs by focusing on issues such as insurance reimbursement, patient confidentiality, ensuring the safety and availability of immune globulin therapy, and maintaining and enhancing patient access to treatment options. Today, thousands of individuals and families affected by primary immunodeficiency diseases depend on IDF for advocacy, education and empowerment.

Proper citation: Immune Deficiency Foundation (RRID:SCR_004674) Copy   

•   Source: SciCrunch Registry

https://computation-rnd.llnl.gov/lmat/

Open-source software tool to assign taxonomic labels to as many reads as possible in very large metagenomic datasets and report the taxonomic profile of the input sample. The quick "single pass" analysis of every read allows read binning to support additional more computationally expensive analysis such as metagenomic assembly or sensitive database searches on targeted subsets of reads.

Proper citation: LMAT (RRID:SCR_004646) Copy   

•   Source: SciCrunch Registry

http://www.autismspeaks.org/

Autism Speaks has grown into the nation''s largest autism science and advocacy organization, dedicated to funding research into the causes, prevention, treatments and a cure for autism; increasing awareness of autism spectrum disorders; and advocating for the needs of individuals with autism and their families. We are proud of what we''ve been able to accomplish and look forward to continued successes in the years ahead. In addition to putting money into new and cutting edge research, we also fund resources and programs such as the Autism Speaks Autism Treatment Network, Autism Speaks������?? Autism Genetic Resource Exchange and several other scientific and clinical programs. Autism Speaks was founded in February 2005 by Bob and Suzanne Wright, grandparents of a child with autism. Their longtime friend Bernie Marcus donated $25 million to help financially launch the organization. At Autism Speaks, our goal is to change the future for all who struggle with autism spectrum disorders. We are dedicated to funding global biomedical research into the causes, prevention, treatments, and cure for autism; to raising public awareness about autism and its effects on individuals, families, and society; and to bringing hope to all who deal with the hardships of this disorder. We are committed to raising the funds necessary to support these goals. Autism Speaks aims to bring the autism community together as one strong voice to urge the government and private sector to listen to our concerns and take action to address this urgent global health crisis. It is our firm belief that, working together, we will find the missing pieces of the puzzle.

Proper citation: Autism Speaks (RRID:SCR_004741) Copy   

•   Source: SciCrunch Registry

http://www.capitalbiosciences.com/

Biological products including Cell Immortalization Products, Clinically Defined Human Tissue, cDNA ORF Clones, Premade Adenoviruses, Purified Proteins, Viral Expression Systems and others as well as services like Custom Recombinant Adenovirus Production, Custom Recombinant Lentivirus Production, Protein Detection and Quantification and Stable Cell Line Production for academic and governmental research institutes, pharmaceutical and biotechnology industry. Capital Biosciences offers most types of human tissues, normal and diseased, with extensive clinical history and follow up information. Standard specimen format: Snap-frozen(flash-frozen), Formalin fixed and paraffin embedded (FFPE) tissues, Blood and blood products, Bone marrow, Total RNA, Genomic DNA, Total Proteins, Primary cell cultures, Viable frozen tissue. Tumor tissue samples include: Bladder cancer, Glioblastoma, Medulloblastoma, Breast Carcinoma, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Head and Neck (H&N) Carcinoma, Hepatocellular Carcinoma (HCC), Hodgkin's lymphoma, Kidney, Renal Cell Carcinoma, Lung Cancer, Non-Small Cell (NCSLC), Lung Cancer, Small Cell (SCLC), Melanoma, Mesothelioma, non-Hodgkin's Lymphoma, Ovarian Adenocarcinoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer.

Proper citation: Capital Biosciences (RRID:SCR_004879) Copy   

•   Source: SciCrunch Registry

http://www.sbtf.org/home.html

Founded in 1995, the Southeastern Brain Tumor Foundation (SBTF), a 501c3 not-for-profit charitable foundation, is devoted to improve the quality of life for brain tumor patients and their families. By offering information, education and support services, we aspire to instill hope, knowledge and comfort to all involved. The Southeastern Brain Tumor Foundation also raises funds for research and medical personnel so that a cure can be found. For over a decade, the SBTF has become a well-known fundraising entity supporting critical, cutting edge brain tumor research at major medical centers in the Southeast. Our annual Race for Research held in Atlanta, Georgia each summer, is our main fundraising event popular throughout Atlanta and the surrounding metropolitan area and has funded over $1.2 million dollars in research grants to leading researchers at major medical centers throughout the Southeast over the past decade. We are proud of our dedicated, all volunteer Board of Directors who meet monthly. Our Board is a diverse group comprised of individuals who''ve been touched by brain tumors in many different ways. Ranging from patients and family members to healthcare professionals; we are all committed to promoting the awareness of brain tumors in the community, communicating with patients and families and raising critical funds for research grants furthering advancements in the treatment of brain tumors. Our monthly support group, lead by a nurse practitioner, welcomes patients and their families to sit side by side with each other, share their experiences, communicate and receive support. As a neurosurgeon-scientist focused on the treatment of patients with brain tumors, I am committed to advancing the mission of SBTF forward in the fight against brain tumors. Our ability to serve the brain tumor community is dependent on each of you. Whether you support us with a financial donation in our fundraising efforts or with your time as a volunteer, each of you are a vital and integral part of our success and we thank you.

Proper citation: Southeastern Brain Tumor Foundation (RRID:SCR_004768) Copy   

•   Source: SciCrunch Registry

http://www.pictar.org

An algorithm for the identification of microRNA targets. Details are provided (3' UTR alignments with predicted sites, links to various public databases etc) regarding: # microRNA target predictions in vertebrates (Krek et al, Nature Genetics 37:495-500 (2005)) # microRNA target predictions in seven Drosophila species (Grn et al, PLoS Comp. Biol. 1:e13 (2005)) # microRNA targets in three nematode species (Lall et al, Current Biology 16, 1-12 (2006)) # human microRNA targets that are not conserved but co-expressed (i.e. the microRNA and mRNA are expressed in the same tissue) (Chen and Rajewsky, Nat Genet 38, 1452-1456 (2006)) co-expressed targets

Proper citation: PicTar (RRID:SCR_003343) Copy   

•   Source: SciCrunch Registry

http://www.bioconductor.org/packages/2.12/bioc/html/minfi.html

Software that improves the results from the Illumina infinium HumanMethylation450 BeadChips by reducing technical variation within and between arrays. SWAN is available in the minfi Bioconductor package.

Proper citation: SWAN (RRID:SCR_003455) Copy   

•   Source: SciCrunch Registry

http://www.astellas.com/

Japanese pharmaceutical company formed from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system. The company's headquarters are in Tokyo, with research centers in Tsukuba and Osaka. Clinical development is centered in Northbrook, Illinois and Leiderdorp, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people. (Wikipedia)

Proper citation: Astellas Pharma Inc. (RRID:SCR_003769) Copy   

•   Source: SciCrunch Registry

http://www.nus.edu.sg/uhc/cps/resources/selfhelp/TSQ.pdf

THIS RESOURCE IS NO LONGER IN SERVICE, documented October 12, 2016. A brief self-report trauma screening tool, simple to administer and score, designed for trauma victims in general. This 10-items scale, all derived from the DSM-IV2 criteria, describes either a reexperiencing symptom of post-traumatic stress disorder (items 1 through 5) or an arousal symptom of PTSD (items 6 through 10). The result of the original study indicate that an excellent prediction of a PTSD diagnosis was provided by respondents endorsing at least 6x re-experiencing or arousal symptoms, for each sample of patients (rail crash survivors and crime victims). Scoring: 0-5 yes responses = Likelihood of No PTSD, 6-10 yes responses = likelihood of PTSD

Proper citation: Trauma Screening Questionaire (RRID:SCR_003675) Copy   

•   Source: SciCrunch Registry

https://www.merck.com/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 27th, 2023. Cubist Pharmaceuticals was American biopharmaceutical company that targeted pathogens like MRSA. Company employed 638 people, mostly in Lexington, MA. On 8 December 2014, Merck acquired Cubist.

Proper citation: Cubist Pharmaceuticals (RRID:SCR_003691) Copy   

•   Source: SciCrunch Registry

http://www.ahrq.gov/data/

Agency that produces evidence to make health care safer, higher quality, more accessible, equitable, and affordable. Funding opportunities, grants, and a large collection of longitudinal hospital care data in the United States including the Systematic Review Data Repository and data sources on healthcare cost, quality, and accessibility, emergency room visits, hospitalization, and medical insurance are available. It works within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used.

Proper citation: Agency for Healthcare Research and Quality (RRID:SCR_003604) Copy   

•   Source: SciCrunch Registry

http://www.efanet.org/

A non-profit network of allergy, asthma and Chronic Obstructive Pulmonary Disease (COPD) patients' organisations, representing 35 national associations in 22 countries and over 400,000 patients. They're dedicated to making Europe a place where people with allergies, asthma and COPD have the best quality care and a safe environment, live uncompromised lives and are actively involved in all decisions influencing their health. They work on behalf of patients to: * Promote awareness of allergies and airways diseases among policymakers and the general public. * Broaden our understanding of these conditions by increased collaboration between national patient associations. * Share knowledge and experience to beneficially educate both the public and EFA members. * Promote patient concerns and opinions within the European institutions and enable national patient associations to gain representation at EU level. * Improve their health and quality of life.

Proper citation: European Federation of Allergy and Airways Diseases Patients Associations (RRID:SCR_003855) Copy   

•   Source: SciCrunch Registry

http://www.alzheimer-europe.org/

A non-governmental organization aimed at raising awareness of all forms of dementia by creating a common European platform through co-ordination and co-operation between Alzheimer organizations throughout Europe. Alzheimer Europe is also a source of information on all aspects of dementia.

Proper citation: Alzheimer Europe (RRID:SCR_003802) Copy   

•   Source: SciCrunch Registry

https://www.biogen.com/en_us/home.html

Global biotechnology company based in Cambridge, Massachusetts, specializing in discovering, developing, and delivering important therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases to patients worldwide.

Proper citation: Biogen Idec (RRID:SCR_003790) Copy   

•   Source: SciCrunch Registry

http://www.amorfix.com/

Product development company focused on therapeutic products and diagnostic devices targeting misfolded protein diseases. On July, 2015 the company name was changed to ProMIS Neurosciences, Inc.

Proper citation: Amorfix (RRID:SCR_003783) Copy   

•   Source: SciCrunch Registry

http://www.nactem.ac.uk/genia/

Resources and tools from a project to automatically extract useful information from texts written by scientists to help overcome the problems caused by information overload. The primary annotated resource created is the GENIA corpus, a collection of biomedical literature which consists of multiple layers of annotation, encompassing both syntactic and semantic annotation. The project also created or coordinated the annotation of multiple other corpus resources. Additionally, a rich set of automatic tools are available for various annotation tasks, most trained on various parts of the GENIA corpus annotations. The GENIA corpus was developed to provide a reference material for the development of bio-TM systems. The corpus currently contains 1,999 Medline abstracts which were collected using the three MeSH terms, human, blood cells, and transcription factors. The corpus has been annotated with various levels of linguistic and semantic information. The GENIA corpus includes the following: * POS annotation * Treebank * Coreference Annotation * Term annotation * Event annotation * Relation annotation * Cellular localization * Disease-Gene association * Pathway corpus The GENIA Project initiated the BioNLP Shared Task series and has organized a number of tasks in three different shared task events, many using resources based on GENIA Corpus annotations. Tools include: * XConc suite: a collection of XML-based tools which are integrated to support the corpus development and annotation.

Proper citation: GENIA Project: Mining literature for knowledge in molecular biology (RRID:SCR_007990) Copy   

•   Source: SciCrunch Registry

http://www.chus.qc.ca/en/

Public healthcare network in Sherbrooke, Quebec, Canada, affiliated with the Université de Sherbrooke Faculty of Medecine.

Proper citation: University of Sherbrooke Hospital Centre; Quebec; Canada (RRID:SCR_008112) Copy   

•   Source: SciCrunch Registry

http://www.alzfdn.org/index.htm

Non profit organization and informational portal directed towards patients and families. AFA is an umbrella orgnization uniting over 1600 member organizations to collaborate on education, resources, best practices and advocacy. AFA provides several grant opportunities for AFA's nonprofit member organizations and to individuals in need.

Proper citation: Alzheimer's Foundation of America (RRID:SCR_008724) Copy   

•   Source: SciCrunch Registry

http://www.tutegenomics.com/

A robust, secure, medical-grade, web application that lives in the cloud and has the ability to analyze and annotate entire human genomes in a rapid and cost-effective way.

Proper citation: Tute Genomics (RRID:SCR_008672) Copy   

•   Source: SciCrunch Registry